Oncology Pipeline

Investigational drugs mentioned are for use in clinical studies only, and may be studied alone or in combination with drugs for indications that have not been approved by the FDA. Approved drugs mentioned are also being studied for uses for which they are not approved. Safety and efficacy have not been established for any of these drugs for the uses being studied. AbbVie in no way intends to recommend or imply that these drugs should be used for unapproved uses.




For a complete list of oncology pipeline molecules see abbvie.com
Venetoclax jointly developed with Roche. Ibrutinib jointly developed with Janssen Biotech. Epcoritamab developed in partnership with Genmab. TTX-030 developed by Trishula Therapeutics through Phase 1b and AbbVie has option to lead global development.
Livmoniplimab was developed in partnership with Argenx. †
ADC=Antibody-Drug Conjugate.
mAb=Monoclonal Antibody.
Antigen Receptor T-Cell.